Anti-IgE na urticária crônica
Anti-IgE in chronic urticaria
Solange Oliveira Rodrigues Valle; Sergio Duarte Dortas Júnior; Soloni Afra Pires Levi; Alfeu Tavares França
Resumo
A urticária é uma condição frequente; consiste de lesões eritematopapulosas pruriginosas, isoladas ou agrupadas, fugazes, geralmente circulares, podendo variar em forma e tamanho. Convencionalmente, a urticária pode ser dividida, quanto a sua duração, em duas formas: aguda e crônica. Na forma crônica as lesões estão presentes diariamente ou quase diariamente, permanecendo menos de 24 horas na maior parte dos casos, durante um período superior a seis semanas, frequentemente tendo impacto na qualidade de vida. A anti-IgE é um anticorpo monoclonal humanizado aprovado para o uso em asma de difícil controle. Atualmente, várias linhas de evidência indicam que a anti-IgE pode ser benéfica no tratamento da urticária espontânea crônica e física. Neste artigo revisamos as principais e atuais publicações sobre o uso de anti-IgE para o tratamento da urticária crônica refratária aos tratamentos convencionais. Outros estudos ainda são necessários para melhor compreender os mecanismos envolvidos na resposta favorável a esta terapia.
Palavras-chave
Abstract
Urticaria is a common condition, consisting of fleeting erythematopapulous pruritic lesions, appearing isolated or grouped, usually circular, but varying in shape and size. Conventionally, hives can be divided into acute and chronic, according to their duration. In the chronic form, lesions are present daily or almost daily, remaining present for less than 24 hours in most cases, over a period longer than 6 weeks, usually with an impact on quality of life. Anti-immunoglobulin E (anti-IgE) is a humanized monoclonal antibody approved for use in difficult-to-control asthma. Currently, several lines of evidence indicate that anti-IgE antibodies can be beneficial in the treatment of chronic spontaneous and physical urticaria. In this paper, we review major and current publications on the use of anti-IgE for the treatment of chronic urticaria refractory to conventional treatment. Further studies are needed to better understand the mechanisms involved in the favorable response of chronic urticaria to this therapy.
Keywords
Referências
1. Parslow TG. Immunoglobulins & Immunoglobulin Genes. In: Parslow TG, Stites DP, Terr AI, Imboden JB (eds.). Medical Immunology. 10ed. Lange Medical Books/McGrawHill; 2001. p. 95-114.
2. Black AK, Greaves MW. Urticaria and Angioedema. In: Kay AB (ed.). Allergy and allergic diseases. Oxford: Blackwell Science Ltda; 1997. p. 1586-607.
3. Kaplan AP. Urticaria and angioedema. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yungiger JW, Busse WW (eds.). Allergy: principles and practice. 4ed. St Louis: Mosby; 1993. p. 1553-80.
4. Zuberbier T, Bindslev-Jensen C, Canonica W, et al; EAACI/GA2LEN/ EDF. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006 Mar;61(3):316-20.
5. Kennard CD. Evaluation and treatment of urticaria. Immunol Allergy Clin N Am. 1995;15:785-801.
6. Mlynek A, Magerl M, Hanna M, et al. The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy. 2009;64:927-36.
7. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009:64:1427‑43.
8. Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and Treatment of urticaria and angioedema : a worldwide perspective. WAO Journal. 2012;5:125-47.
9. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Inmmunol. 2011;128:567-73.
10. Long AA. Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs. 2009 May-Jun;1(3):237-46.
11. Plosker GL, Keam SJ. Omalizumab – a review of its use in the treatment of allergic asthma. BioDrugs. 2008;22(3):189-204.
12. http://www.portal.novartis.com.br/UPLOAD/ImgConteudos/1815. pdf.
13. Miller CW, Krishnaswamy N, Johnston C, et al. Severe asthma and the omalizumab option. Clin Mol Allergy. 2008;6:4.
14. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005 Mar;115(3):459-65.
15. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002 Nov;20(5):1088-94.
16. Stokes J, Casale TB. Anti-IgE therapy. In: Adkinson NFJ,Bochner BS, Busse W, Holgate S, Lemanske RFJ, Simons FER, eds. Middleton’s allergy principes and practice. 7th ed. Philadelphia: Mosby Elsevier; 2009. p. 1679-89.
17. Berger W, Gupta N, McAlary M, et al. Evaluationof long-term safety of the anti-IgE antibody, omalizumab inchildren with allergic asthma. Ann Allergy Asthma Inmmunol. 2003;91:182-8.
18. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008 Jun;63(6):670-84.
19. Presta L, Shields R, O’Connell L, et al. The binding site on human immunoglobulin E for its highaffinity receptor. J Biol Chem. 1994;269:26368-73.
20. Francés L, et al. Omalizumab en el tratamiento de la urticaria crónica. Actas Dermosifiliogr. 2013. http://dx.doi.org/10.1016/j. ad.2013.06.002
21. Mirkina I, Schweighoffer T, Kricek F. Inhibition of human cord bloodderived mast cell responses by anti-Fc epsilonRI mAb 15/1 versus anti-IgE omalizumab. Inmmunol Lett. 2007;109:120-8.
22. Saavedra M, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy. 2011;9:2.
23. Malveaux F, Conroy M, Adkinson N, et al. IgE receptor on human basophils: Relationship to serum IgE concentration. J Clin Invest. 1978;62:176-81.
24. MacGlashan Jr D, McKenzie-White J, Chichester K, et al. In vitro regulation of Fc(epsilon)RI expression on human basophils by IgE antibody. Blood. 1998;91:1633-43.
25. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004;113:297-302.
26. Sánchez-Machín I, Iglesias-Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin Mol Allergy. 2011;9:11.
27. Iemoli E, Piconi S, Fusi A, et al. Immunological effects of omalizumab in chronic urticaria: A case report. J Invest Allergol Clin Immunol. 2010;20:252-4.
28. Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3(1):29.
29. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001,108:184-90.
30. Mankad VS, Burks AW. Omalizumab: other indications and unanswered questions. Clin Rev Allergy Immunol. 2005;29:17-30.
31. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Downregulationof FcεRI expression on human basophils during in vivo treatment of atopic patients with anti- IgE antibody. J Immunol 1997;158:1438‑45.
32. Beck LA, Marcotte GV, MacGlashan DW Jr, et al. Omalizumab induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004,114:527-30.
33. Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clinical and Molecular Allergy. 2011;9:2.
34. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99:190-3.
35. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415-8.
36. Güzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563-5.
37. Godse K. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol. 2008;74(2):157.
38. Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247-9.
39. Otto HF, Calabria CW. A case of severe refractory chronic urticaria: a novel method for evaluation and treatment. Allergy Asthma Proc. 2009;30:333-7.
40. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronicspontaneous urticaria with omalizumab. J Allergy Clin Immunol. 2010;126:665-6.30.
41. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol. 2010;90:443-4.
42. Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65(11):1494-5.
43. Waibel KH, Reese DA, Hamilton RG, et al. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010;125(2):490-1.
44. Romano C, Sellitto A, de Fanis U, et al. Maintenance of remission with low-dose omalizumab inlong-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104:95-7.
45. Bullerkotte U, Wieczorek D, Kapp A, et al. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65:931-2.
46. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol. 2010;35(4):e127-9.
47. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65:138-9.
48. Al-Ahmad M. Omalizumab therapy in three patients with chronic autoimmune urticaria. Ann Saudi Med. 2010;30(6):478-81.
49. Groffik A, Mitzel-Kaoukhov H, Magerl M, et al. Omalizumab – an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy. 2011;66(2):303-5.
50. Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177-80.
51. Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol. 2011;56(4):444.
52. Duchini G, Bäumler W, Bircher AJ, et al. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed. 2011;27(6):336-7.
53. Büyüköztürk S, Gelincik A, Demirtürk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey. J Dermatol. 2012;39(5):439-42.
54. Ivyanskiy I, Sand C, Francis ST. Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol. 2012;4:19-26.
55. Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012;4(6):357-61.
56. Brodská P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol. 2012 Sep;4(3):275-80.
57. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixeddose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013 Feb;110(2):113-7.
58. Lefévre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol. 2013 May;25(2):242-5.
59. Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, et al. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther. 2013 May-Jun;26(3):257-9.
60. Le Moing A, Bécourt C, Pape E, et al. Effective treatment of idiopathic chronic cold urticaria with omalizumab: Report of 3 cases. J Am Acad Dermatol. 2013 Aug;69(2):e99-e101.
61. Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013 Sep;13(9):1225-8.
62. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc. 2013 Sep;34(5):446-52. [Abstract]
63. Kaplan AP, Joseph K, Mayjut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticarial with omalizumab. J AllergyClin Inmmunol. 2008;122:569-73.
64. Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, et al. Omalizumab is effective in non autoimmune urticaria. J Allergy Clin Immunol. 2011;127(5):1300-2.
65. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M,Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Inmmunol. 2011;128:202-9.
66. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 7;368(10):924-35. [Erratum in N Engl J Med. 2013 Jun 13;368(24):2340-1.]
67. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul;132(1):101-9.
Submetido em:
30/09/2013
Aceito em:
26/11/2013
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email